Details of the Drug Combination

General Information of Drug Combination (ID: DC47C7H)

Drug Combination Name
ARRY-162 Sotrastaurin acetate
Indication
Disease Entry Status REF
Uveal Melanoma Phase 1 [1]
Component Drugs ARRY-162   DM1P6FR Sotrastaurin acetate   DME53YS
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of ARRY-162
Disease Entry ICD 11 Status REF
Melanoma 2C30 Approved [2]
ARRY-162 Interacts with 2 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
MAPK/ERK kinase kinase (MAP3K) TTROQ37 NOUNIPROTAC Modulator [4]
ERK activator kinase (MEK) TTZCRP3 NOUNIPROTAC Inhibitor [2]
------------------------------------------------------------------------------------
ARRY-162 Interacts with 2 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [5]
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [5]
------------------------------------------------------------------------------------
ARRY-162 Interacts with 2 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 1A2 (CYP1A2) DEJGDUW CP1A2_HUMAN Metabolism [6]
UDP-glucuronosyltransferase 1A1 (UGT1A1) DEYGVN4 UD11_HUMAN Metabolism [7]
------------------------------------------------------------------------------------
Indication(s) of Sotrastaurin acetate
Disease Entry ICD 11 Status REF
Renal transplantation NE84 Phase 2 [3]
Sotrastaurin acetate Interacts with 3 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Protein kinase C alpha (PRKCA) TTFJ8Q1 KPCA_HUMAN Inhibitor [3]
Protein kinase C theta (PRKCQ) TT8QL1J KPCT_HUMAN Inhibitor [3]
Protein kinase C beta (PRKCB) TTYPXQF KPCB_HUMAN Inhibitor [3]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT01801358) A Phase Ib/II Study of AEB071 and MEK162 in Adult Patients With Metastatic Uveal Melanoma
2 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
3 Emerging drugs for psoriasis. Expert Opin Emerg Drugs. 2009 Mar;14(1):145-63.
4 MEK and the inhibitors: from bench to bedside. J Hematol Oncol. 2013; 6: 27.
5 The impact of P-glycoprotein and breast cancer resistance protein on the brain pharmacokinetics and pharmacodynamics of a panel of MEK inhibitors. Int J Cancer. 2018 Jan 15;142(2):381-391.
6 FDA Label of Binimetinib. The 2020 official website of the U.S. Food and Drug Administration.
7 Binimetinib - European Medicines Agency - European Union